|
KMID : 0360319920240050759
|
|
Journal of Korean Cancer Research Association
1992 Volume.24 No. 5 p.759 ~ p.766
|
|
|
A Comparison of the Acute Antiemetic Effect of Ondansetron with Combination of Metoclopramide, Dexamethasone, Lorazepam in Patients Receiving Cisplatin
|
|
백승호
차미경/조용욱/오도연/김선주
|
|
|
Abstract
|
|
|
Background. In spite of possible effects for emesis following chemotherapy including high dose cisplatin, nausea and vomiting are the most troublesome problem in cancer treatment. Ondansetron, a selective antagonist of serotonin S3 receptors, is
effective in the prevention of emesis associated with chemotherapeutic agents, especially high cisplatin.
Methods. 19 patients with solid cancer scheduled to receive cisplatin containing chemotherapy were studied, and we compared the efficacy and safety of ondansetron with those of intravenous high dose metoclopramide(1.5mg/kg) plus
dexamethasone(10mg
i.v.)
and lorazepam(2mg i.v)(MDL therapy) to control the acute emesis induced by high-dose cisplatin(>50mg/m*) treatment. Ondansetron was administered in dose of 8mg intravenous bolus followed by a infusion of 1mg/hour 24 hours as recommended schedule
for the
prophylaxis of acute cisplatininduced emesis.
Results. Ondansetron showed significantly grater rate of the complete response than that of MDL therapy(63.2% vs 31.2%) for controlling of acute emesis on the first day of treatment(p<0.05). Also ondansetron showed significantly lower grade of
nausea
than in comparable MDL therapy(p<0.05). Side effects attributable to ondansetron were mild: headache in 4 patients, diarrhea in 1 patient, sedation in 1 patient and abdominal pain in 1 patient. Therefore, ondansetron exhibited minimal toxicity
with
no
extrapyramidal effects.
Conclusions. Ondansetron was well tolerable and least as effective as MDL therapy in controlling acute cisplatin-induced emesis.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|